Clinical trials: TACE, open to volunteers
Unresectable Hepatocellular Carcinoma
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC.
- Trial name
- NCT06896396
- Testing
- Lenvatinib, Pembrolizumab, Icaritin soft capsules, TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhiyong Huang
Unresectable Hepatocellular Carcinoma (HCC)
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07408804
- Testing
- TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib), Lenvatinib
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- Bangladesh Medical University
Hepatocellular Carcinoma (HCC)
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC).
- Trial name
- NCT07019844
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- VA Office of Research and Development
Hepatocellular Carcinoma Non-resectable
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy…
- Trial name
- NCT06561399
- Testing
- TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
- Where
- 4 sites in China
- Volunteers
- 28 people
- Sponsor
- Fujian Provincial Hospital
Liver Cancer
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with…
- Trial name
- NCT06353126
- Testing
- DEB-TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved.
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
- Trial name
- NCT06740370
- Testing
- TACE, Lenvatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated…
- Trial name
- NCT07682454
- Testing
- Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
This study will evaluate the safety and efficacy of DEB-TACE with visualable embolization microspheres versus PVA microspheres for hepatocellular carcinoma.
- Trial name
- NCT06190665
- Testing
- DEB-TACE with visualable microspheres, DEB-TACE with PVA microspheres
- Where
- 2 sites in China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma (HCC), Artificial Intelligent
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although curative surgical resection improves survival for early-stage HCC patients, the 5-year postoperative recurrence…
- Conditions
- Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACE
- Trial name
- NCT07417800
- Testing
- AI adjuvant therapy
- Where
- China
- Volunteers
- 11,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma, HCC
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC).
- Trial name
- NCT04472767
- Testing
- Nivolumab, Ipilimumab, Cabozantinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Hepatocellular Carcinoma
The Efficacy of Sequential RT After Triple Therapy for uHCC
Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07052448
- Testing
- sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma (HCC), Cachexia
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
Primary Objective: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on body weight and appetite in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and…
- Conditions
- Hepatocellular Carcinoma (HCC), Cachexia, Anorexia, Malnutrition
- Trial name
- NCT07565415
- Testing
- Nanocrystalline megestrol acetate
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma (HCC), Immunotherapy
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable…
- Conditions
- Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4
- Trial name
- NCT07128251
- Testing
- TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab
- Volunteers
- 47 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Although resection provided survival benefit for selected HCC patients with PVTT, the recurrence rate is still high for those patients.
- Trial name
- NCT06031285
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
- Trial name
- NCT06371157
- Testing
- AK104, Lenvatinib, TACE
- Where
- 4 sites in China
- Volunteers
- 469 people
- Sponsor
- Akeso
Hepatocellular Carcinoma (HCC), TACE
DEB-TACE vs cTACE in HCC After TIPS
This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional…
- Conditions
- Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
- Trial name
- UPGRADE (NCT07322848)
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 206 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Immunotherapy
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years after surgery.
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Preoperative
- Trial name
- NCT05613478
- Testing
- Camrelizumab, Apatinib Mesylate, Radical surgery
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis)
Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France.
- Conditions
- Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis), Bone Cancer Metastatic, Bone Cancer Tumor
- Trial name
- PreciseOnco (NCT07636148)
- Where
- 3 sites in France, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- Mark C Burgmans, MD PhD